Supplementary Material - Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials

Name: Supplementary Material - Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials
Creator: Melinda Gooderham
Published: 2025-03-03T14:57:41.758Z
Keywords: Dermatology, Inflammation, Clinical Trial, Eczema, Contact Dermatitis, Phase III Trials, Janus Kinase

Gooderham, Melinda; Molin, Sonja; Bissonnette, Robert; Worm, Margitta; Crépy, Marie-Noëlle; Stingeni, Luca; Warren, Richard; Schliemann, Sibylle; Schuttelaar, Marie Louise Anna; Ferrucci, Silvia; Serra-Baldrich, Esther; Silverberg, Jonathan; Balita-Crisostomo, Cherry Lou; Oesterdal, Marie Louise; Plohberger, Ursula; Agner, Tove

doi:10.17632/rjrvyss2vg.1

Supplementary Material - Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials

Published: 3 March 2025| Version 1 | DOI: 10.17632/rjrvyss2vg.1

Contributors:

Melinda Gooderham, Sonja Molin, Robert Bissonnette, Margitta Worm, Marie-Noëlle Crépy, Luca Stingeni, Richard Warren, Sibylle Schliemann, Marie Louise Anna Schuttelaar, Silvia Ferrucci, Esther Serra-Baldrich, Jonathan Silverberg, Cherry Lou Balita-Crisostomo, Marie Louise Oesterdal, Ursula Plohberger, Tove Agner

Description

Supplementary Information to accompany and support the manuscript: Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials

Files

Funding

LEO Pharma A/S

Supplementary Material - Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials

Description

Files

Categories

Funding

Licence